More Oncology Drugs Available In U.S., But Australians Pay 30% Less - Tufts Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The evidence-based approach adopted by Australia has led to lower prices, improving the affordability of those medications considered cost-effective for payers and patients by the reimbursement authority, the report says.
You may also be interested in...
Aussie Health Chief Vows To End Delay In Doctor PBS Prescriptions
Australia's health minister says the government is taking steps to ease some of the delays in physician ability to prescribe covered drugs
Building A New Model For Developing New Therapies: An Interview With AstraZeneca's Strategic Alliance Asia Director Richard Wang
Although AstraZeneca is paring down its pipeline by halting discovery efforts in 10 specific diseases, which account for 25 percent of the total diseases that earlier drove research by AstraZeneca ("The Pink Sheet" Daily, March 2, 2010), it won't stop R&D expansion plans in China. As big pharmaceutical firms compete to find the next generation of innovative drugs, translational science may help companies to find the right drug for the right patient and bring these medicines to market faster. During the recent Asia Pharma R&D Leaders conference in Shanghai, Richard Wang, AstraZeneca's Director of Strategic Alliances - Asia, sat down with PharmAsia News' Shanghai Bureau to discuss the strategy of AstraZeneca's Innovation Center China and how translational science is helping the company develop new compounds.
Australia Questions Soliris Survival Benefit; Adds Listings From MSD, Novartis, Janssen To PBS
PERTH, Australia - Australia's Minister of Health Nicola Roxon requested advice from the Pharmaceutical Benefits Advisory Committee on the potential benefits of adding Alexion's Soliris (eculizumab) to the government's Life Saving Drugs Program (LSDP)